The ASAS40 and all major secondary endpoints for Ixekizumab Q4W and Q2W were met at Wk 16 and Wk 52 with no unexpected safety findings. IXE superior to PBO for improving signs, symptoms, and inflammation on MRI in pts with nr-axSpA abstract #2729 #ACR19 @RheumNow

#ACR19 - AM session re:classification vs diagnostic criteria, referencing 2016 Sjogrens Guidelines 1. Designed for rsrch 2. May miss important cases (lower sensitivity) 3. Not intended for diagnosis Remember this when using them in practice! @RheumNow https://t.co/KHWyVYjOjM https://t.co/xyOpkh9mSC

• 2016 American College of Rheumatology/European League Against Rheumatism classi…

Killed zoster vaccine was safe with no flare of RA and PsA We need to know if response was good. #ACR19 @RheumNow abst2093 https://t.co/xp2Ju5wZWK

Do you combine bDMARD with apremilast? #ACR #ACR19 @RheumNow abstract 1481

retrospective study using Medicare claims data demonstrates lower risk of infection-related hospitalization with abatacept compared to other biologics, in RA patients previously exposed to TNFi. Abstr#1801 #ACR19 @RheumNow

ICIR data showing Checkpoint inhibitor-related Sjogrens is different! More men, older patients, seronegative. Dry mouth >>dry eyes. Abstr#1905 #ACR19 @RheumNow @LCalabreseDO #cleclinicrheum

PREVENT trial of Secukinumabnr-axSpA. SEC 150 mg loading and no loading dose provided significant improvement in signs and symptoms of nr-axSpA through Wk 16. The safety profile of SEC was consistent with the established safety profile across indications #L2 #ACR19 @RheumNow

The cytokine storm syndromes including MAS, HLH, autoinflammatory disease. Cron R #ACR19 #acrbest @RheumNow https://t.co/oy2QPHk8jh

Immune-mediated causes of uveitis • Behcet’s disease • Cogan’s syndrome • IBD • TINU • JIA • Multiple sclerosis • Psoriatic arthritis/ AS/ Reactive Arthritis • Relapsing polychondritis • Sarcoidosis • SLE • Vasculitis • Vogt-Koyanagi-Harada Syndrome #ACR19 @RheumNow

MTX v. Mycophenolate – FAST uveitis trial – 265 adults with non-infectious uveitis – Oral MTX 25 mg v. MMF 3 grams daily – MTX non-inferior to mycophenolate Ophthalmology, 2018. 125(2):193. JAMA, 2019. 322(10):936. #ACR19 @RheumNow

Abstract #0626 Are there really differences between non-radiographic and radiographic axial spondyloarthritis? Data from the Spanish Atlas #ACR19 @RheumNow https://t.co/hg3U2QjpFp

More than half of rheums who tweet and answer polls at #acr19 don’t look at synovial fluid anymore (maybe even more don’t in the real world) due to time constraints— your thoughts? @Rheumnow https://t.co/78d6MwbsXB

• k dao on Twitter: "Do you still look at synovial fluid under the microscop…

Poor prognostic factors for MDA-5 ILD: - Ferritin > 1000 ng/mL prior Rx - GCO or consolidations in all lung fields - Worsening of lung consolidations during Rx #ACR19 @RheumNow

Myositis -- Ask for muscle biopsy when: - high clinical suspicion w/ negative myositis specific antibodies - high clinical suspicion of inherited muscle disease - isolated elevated CPK - recalcitrant to treatment - atypical presentation #ACR19 @RheumNow

Sjogrens RCT of Tocilizumab showed no benefit. Wonder re outcomes and pt selection. Maybe pick early pts with high inflammatory markers or other organ involvement #ACR @RheumNow #Sjogrens abstr1904